Clinical Trials Directory

Trials / Completed

CompletedNCT05305534

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study

Clinical Performance Evaluation Study of the QIAstat-Dx® BCID GN and GPF Plus AMR Panels on Positive Blood Culture and Pure Colony Isolates From Subjects With Signs and Symptoms of Bloodstream Infection

Status
Completed
Phase
Study type
Observational
Enrollment
2,142 (actual)
Sponsor
QIAGEN Gaithersburg, Inc · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods

Detailed description

This multicenter study aims to evaluate the performance of QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel with another validated comparator method.

Conditions

Interventions

TypeNameDescription
DEVICEQIAstat-Dx® BCID GN and GPF Plus AMR PanelsThe performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested

Timeline

Start date
2023-12-01
Primary completion
2025-04-10
Completion
2025-08-25
First posted
2022-03-31
Last updated
2025-09-24

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05305534. Inclusion in this directory is not an endorsement.

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study (NCT05305534) · Clinical Trials Directory